LEADER 00900nam0-22003131--450- 001 990009168570403321 005 20101013093209.0 010 $a0300050445 035 $a000916857 035 $aFED01000916857 035 $a(Aleph)000916857FED01 035 $a000916857 100 $a20100406d1991----km-y0itay50------ba 101 0 $aeng 102 $aUS 105 $ay-------001yy 200 1 $aChange and continuity in seventeenth century England$fChristopher Hill 205 $aRev. ed 210 $aNew Haven$cYale university press$dc1991 215 $aXIV, 378 p.$d22 cm 676 $a941$v11 rid.$zita 700 1$aHill,$bChristopher$f<1912-2003>$0323063 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990009168570403321 952 $aSDI-KF 866$b3677$fSDI 959 $aSDI 996 $aChange and continuity in seventeenth century England$9780468 997 $aUNINA LEADER 04524nam 22006015 450 001 9910254558503321 005 20251116155557.0 010 $a3-319-34211-8 024 7 $a10.1007/978-3-319-34211-5 035 $a(CKB)3710000000726854 035 $a(DE-He213)978-3-319-34211-5 035 $a(MiAaPQ)EBC4556310 035 $a(PPN)194376095 035 $a(EXLCZ)993710000000726854 100 $a20160610d2016 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPI3K-mTOR in Cancer and Cancer Therapy /$fedited by Nandini Dey, Pradip De, Brian Leyland-Jones 205 $a1st ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Humana,$d2016. 215 $a1 online resource (XXIV, 294 p. 31 illus. in color.) 225 1 $aCancer Drug Discovery and Development,$x2196-9906 311 08$a3-319-34209-6 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aPI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities. 330 $aIn the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway?s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area. 410 0$aCancer Drug Discovery and Development,$x2196-9906 606 $aCancer$xResearch 606 $aMolecular biology 606 $aDrug resistance 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aDrug Resistance$3https://scigraph.springernature.com/ontologies/product-market-codes/B16020 615 0$aCancer$xResearch. 615 0$aMolecular biology. 615 0$aDrug resistance. 615 14$aCancer Research. 615 24$aMolecular Medicine. 615 24$aDrug Resistance. 676 $a616.994071 702 $aDey$b Nandini$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aDe$b Pradip$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aLeyland-Jones$b Brian$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910254558503321 996 $aPI3K-mTOR in Cancer and Cancer Therapy$92528918 997 $aUNINA